Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma.

ABSTRACT:

Background and aims

Combination atezolizumab/bevacizumab is the gold standard for first-line treatment of unresectable hepatocellular carcinoma (HCC). Our study investigated the efficacy and safety of combination therapy in older patients with HCC.

Methods

191 consecutive patients from eight centres receiving atezolizumab and bevacizumab were included. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and disease control rate (DCR) defined by RECIST v1.1 were measured in older (age ≥ 65 years) and younger (age < 65 years) age patients. Treatment-related adverse events (trAEs) were evaluated.

Results

The elderly (n = 116) had higher rates of non-alcoholic fatty liver disease (19.8% vs. 2.7%; p < .001), presenting with smaller tumours (

SUBMITTER: Vithayathil M 

PROVIDER: S-EPMC9825835 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature